(untitled) - Sehn, L
Outcomes From the Phase 3 inMIND Study of Tafasitamab (Tafa) Plus Lenalidomide (Len) and Rituximab (R) for Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL). ICML 2025; Oral Session 028